| Also known as |
EIDD-2801 |
| Blood pressure |
No significant effects |
| Chemical name |
ОІ-D-N4-hydroxycytidine |
| Dosage (medical) |
800 mg twice daily for 5 days |
| Dosage (sports) |
Not applicable |
| Effects |
Reduces the risk of hospitalization or death in COVID-19 patients |
| Formula |
C13H19N3O7 |
| Half-life |
Approximately 7 hours |
| Hepatotoxicity |
Low |
| Lab Test |
Not specific |
| Main action |
Induces viral mutagenesis |
| Side effects |
Diarrhea, nausea, dizziness |
| Storage conditions |
Store at room temperature, away from moisture and heat |
| Strength |
200 mg |
| Substance class |
Antiviral medication |
| Trade name |
Lagevrio |
| Use in sports |
None |
| Water Retention |
None |
| Manufacturer |
Healing Pharma |
